NIH funds study to evaluate remdesivir for COVID-19 in pregnancy
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who
A forum for researchers, students and applicants in the field of cyclodextrin technology
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
RotaChrom Technologies, the developer of the world’s first industrial-scale Centrifugal Partition Chromatography (CPC) technology platform, announced today the launch of
Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19
Current formulations of remdesivir are required to be administered intravenously due to the drug’s low solubility, with each infusion taking
Currently, remdesivir is only available as a lyophilized powder for reconstitution and intravenous53 infusion and concentrate solution for dilution and
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States — — Veklury Shortened Time to
Remdesivir, an investigational broad-spectrum antiviral agent, formulated with sulfobutyl beta-cyclodextrin, has shown in vitro activity against SARSCoV-2. Currently, remdesivir is